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Abstract 
 
Understanding how human genetic variation impacts individual response to immunogens is fundamental 
for rational vaccine development. To explore host mechanisms involved in cellular immune responses to 
the MRKAd5 HIV-1 gag/pol/nef vaccine tested in the Step trial, we performed a genome-wide 
association study of determinants of HIV-specific T cell responses, measured by IFN-γ ELISpot assays. 
No human genetic variant reached genome-wide significance, but polymorphisms located in the Major 
Histocompatibility Complex region showed the strongest association with response to the HIV-1 Gag 
protein: HLA-B alleles known to associate with differences in HIV-1 control were responsible for these 
associations. The implication of the same HLA alleles in vaccine-induced cellular immunity and in 
natural immune control is of relevance for vaccine design. Furthermore, our results demonstrate the 
importance of considering the host immunogenetic background in the analysis of immune responses to T 
cell vaccines. 
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The Step trial was a Phase IIb proof-of-concept study conducted by the HVTN and Merck designed to 
assess the safety and efficacy of a 3-dose regimen of the Merck adenovirus serotype 5 HIV-1 gag/pol/nef 
vaccine (MRKAd5 HIV-1 gag/pol/nef), a replication-defective Ad5 vaccine expressing Gag, Pol, and Nef 
proteins from an HIV-1 Clade B strain, aiming to elicit cellular immune responses. It was a multicenter, 
double-blind, randomized, placebo controlled study performed in adults at high risk of HIV-1 infection 
[1]. Vaccinations in the trial were terminated following a planned interim analysis in September 2007 
because of a lack of efficacy of the tested vaccine. Vaccination was not associated with a lower viral load 
in subjects who became infected, and the rate of HIV-1 acquisition was actually higher among vaccine 
recipients than in placebo recipients, particularly in the subgroup of uncircumcised male subjects with 
high pre-existing adenovirus serotype 5 (Ad5) neutralizing antibody titers [1, 2]. Understanding this 
disappointing and paradoxical outcome is a high priority for the field. 
 
Recombinant Ad5 vaccine candidates had previously been shown to elicit strong cellular immune 
responses against HIV-1 epitopes [3, 4]. Accordingly, the MRKAd5 HIV-1 gag/pol/nef vaccine was 
highly immunogenic for inducing HIV-specific T cell responses: at least three-quarters of vaccine 
recipients generated a response to one or more of the HIV-1 proteins included in the vaccine [2]. Still, 
those responses were quantitatively highly variable: higher response rates were observed in participants 
with low pre-existing Ad5 neutralizing antibody titers [2], but a significant fraction of variability in 
response intensity remains unexplained and could be at least partially attributable to human genetic 
variation.  
 
Thanks to recent advances in genomics, technology and bioinformatics, it is now possible to 
comprehensively assess associations of common human genetic variants with biological phenotypes [5]: 
here we combine whole-genome genotyping results and HLA class I typing data to explore the host 
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mechanisms associated with variability in T cell responses to the HIV-1 proteins present in the MRKAd5 
HIV-1 gag/pol/nef vaccine tested in the Step trial.  
 
Methods 
 
Subjects: Study participant enrollment inclusion and exclusion criteria for the Step study have been 
described previously [1]. Each participant provided informed consent for genetic testing. All male Step 
trial participants who received at least two doses of the MRKAd5 HIV-1 gag/pol/nef vaccine and were 
HIV-1 seronegative at week eight, i.e., four weeks after the second vaccination, were eligible for our 
study. This investigation was initiated after the interim analysis when all but one of the cases identified 
were males [1]. Most immunogenicity and covariate analyses subsequently performed were confined to 
male participants, and accordingly this study was restricted to male vaccine recipients. 
 
Immunological assays: Validated interferon gamma (IFN-γ) ELISpot assays were run on previously 
cryopreserved PBMCs that were obtained at week eight: the Merck laboratory (Merck) tested a quarter of 
the samples, randomly selected and stratified by treatment assignment and study site. The HVTN 
laboratory at Fred Hutchinson Cancer Research Center laboratory (HVTN) tested the remaining samples. 
Cells were stimulated ex vivo with pools of peptides that were 15 amino acids in length and overlapping 
in sequence by 11 amino acids. The peptide sequences matched the HIV-1 proteins encoded by the 
vaccine, and a total of four non-overlapping pools of peptides were tested: one Gag, two Pol, and one Nef 
pools. If any of the protein-level responses was positive, the overall response was considered positive. 
Responses were reported as the number of spot-forming cells per million PBMC. A sample was 
considered positive if the background-adjusted mean of the experimental wells was ≥ 4 x the mean of the 
negative controls and ≥55 SFC/10^6 PBMC for the assays run at the Merck Laboratory, while positivity 
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was assessed using a bootstrapping method specifically developed for in-house ELISpot data for the 
samples run at HVTN [6, 7]. We also compared the HIV-1 specific IFN-γ ELISpot results to CD4+ and 
CD8+ T-cell responses measured on a subset of samples by IFN-γ and interleukin-2 (IL-2) intracellular 
cytokine staining (ICS) assays [2]. 
 
Genotyping: DNA samples were genotyped using the Human1M-Duo Infinium HD BeadChip (Illumina), 
which features more than one million single nucleotide polymorphisms (SNPs) and an additional 52,167 
markers designed to specifically target copy number variant regions. We also inferred larger copy number 
variants from the genotyping data using the PennCNV software [8]. A series of data cleaning and quality 
control procedures were carried out: SNPs were filtered based on missingness (dropped if called in <99% 
of subjects), minor allele frequency (dropped if <0.005) and Hardy-Weinberg Equilibrium deviation. 
Study subjects were filtered based on genotyping quality, a gender check (heterozygosity testing) and 
cryptic relatedness (sharing of genetic information was first predicted by estimating identity by descent 
(IBD); then one sample in each pair of DNA samples showing >12.5% of IBD was excluded). High-
resolution HLA class I typing (4 digits HLA-A, HLA-B and HLA-C) was obtained using sequence-based 
methods. 
 
Association analysis: SNPs, copy number variants and HLA class I alleles were tested for association 
with IFN-γ ELISpot responses to Gag, Pol and Nef in regression models that also included age, pre-
vaccination Ad5 serology titers and the laboratory in which the ELISpot assay was performed (HVTN vs. 
Merck) as covariates. In addition, to correct for population stratification, we applied a modified 
EIGENSTRAT method [9], which is a principal component analysis of the genotyping data, to define 
ethnic groups and correct for residual population ancestry within each group. The analyses were run 
separately in three ethnic groups using PLINK [10]. Combined P values for all three populations were 
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obtained using the Stouffer’s weight Z-method [11]. We used linear regression to test for association 
between genetic variants and natural log-transformed quantitative ELISpot responses, and logistic 
regression for qualitative assessment of the ELISpot responses (case-control comparisons between 
individuals with or without detectable responses to the HIV-1 peptide pools). Significance was assessed 
with a straight Bonferroni correction (threshold for genome-wide significance: P=5E-08). Power 
calculations were performed using the PowerCalc software (Lan L, Wang S & Feng S. GWASPower/QT: 
a statistical power calculation software for genome-wide association studies with quantitative traits in 
natural populations, submitted), available at http://www.genome.duke.edu/labs/goldstein/software. 
 
Results 
 
Participants and samples: A total of 831 subjects were eligible for the study. They all were male vaccine 
recipients and HIV-1 negative at week eight. However, 36 of them became infected later in the study. 
Participants were enrolled in nine countries in the Americas and Australia, and self-reported ethnicities 
were very diverse, with a majority of white and multi-racial individuals (Table 1). All DNA samples were 
run on Human1M-Duo chips: 22 samples were excluded because of insufficient genotyping quality; three 
individuals were excluded because of cryptic relatedness: one in each of two pairs of 100% identical 
genotypes and one in a pair of 50% identical genotypes; and two subjects were excluded because of a 
gender discrepancy between genotype and the phenotypic database (females misclassified as males).  
 
Immunological assays: Of the 831 samples, 792 had sufficient cryopreserved PBMCs to be tested in IFN-
γ ELISpot assays: 30.6% were analyzed by Merck (N=242) and 69.4% by the HVTN (N=550). IFN-γ 
ELISpot responses were detected in 85.2% (675/792) of the vaccine recipients. The percentages of 
subjects with positive responses were 75.6% for Gag, 69.3% for Nef, and 63.6% and 55.3% for the two 
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Pol peptide pools. Gag-specific expression of IFN-γ and/or IL-2 measured by ICS assays gated on CD4+ 
and CD8+ T-cell populations, available for 150 samples [2], were compared to Gag-specific responses 
measured by IFN-γ ELISpot assays (Figure 1): we observed a strong correlation between ELISpot results 
and CD8+ T-cell responses (r2=0.4, P<0.001), but no correlation with CD4+ T-cell responses (r2=0.05, 
P=0.1).  
 
Population structure: Altogether, 768 subjects had complete genotype and phenotype results (Table 1). 
To avoid spurious associations due to population structure, we ran separate analyses in three ethnic 
groups corresponding to the major clusters identified in the principal component analysis of the 
genotyping data. After removal of individuals who could not be classified into a homogeneous group, a 
total of 318 white, 87 black and 115 Mestizo subjects were available for regression analyses (Table 2). 
The study had 80% power to detect genetic variants explaining at least 6.6% of the variability in 
quantitative HIV-1 specific responses in the combined population. 
 
Association analysis: The genome-wide analyses did not reveal any significant association between IFN-γ 
ELISpot responses to Gag, Pol or Nef and SNPs or copy number variants after correction for multiple 
testing. However, in the analysis of association with quantitative responses to Gag, the SNPs with the 
lowest P values clustered in the Major Histocompatibility Complex (MHC) region, around the HLA-B and 
HLA-C genes (Figure 2); no such clustering was observed for Pol or Nef associations. Therefore, we 
tested all 4-digit HLA class I alleles present in the study population for association with the same 
phenotype. In whites with positive Gag-specific responses (N=265), three HLA-B alleles associated with 
higher response: HLA-B*2705 (N=27, P=4.6E-05), B*5101 (N=29, P=0.02) and B*5701 (N=17, 
P=0.05); whereas two alleles associated with lower responses: HLA-B*0801 (N=60, P=2.7E-04) and 
B*4501 (N=5, P=0.01) (Figure 3). Together, these HLA-B alleles accounted for 13.6% of the variability 
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in Gag responses. No significant association was found in the smaller groups of black and Mestizo 
individuals, although a trend toward higher Gag responses was observed for HLA-B*5703 (P=0.1). We 
did not observe any significant association between HLA-C alleles and quantitative responses to Gag.  
We then tested whether the identified HLA-B alleles were responsible for the association signals detected 
in the MHC region in the genome-wide scan, using nested linear regression. When added to regression 
models that already incorporated HLA-B*2705, B*5101, B*5701, B*0801 and B*4501 as covariates, the 
SNPs that showed the strongest associations in the GWAS did not result in a significant increase in the 
explained variation, confirming that the GWAS signals are indeed explained by the combined effect of 
functional HLA alleles (Table 3). 
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Discussion 
 
In an attempt to better delineate the host mechanisms involved in the immune response to T cell vaccines, 
we performed a genome-wide association study searching for human genetic determinants of the inter-
individual variability observed in cellular immune responses to the MRKAd5 HIV-1 gag/pol/nef vaccine. 
HIV-1 specific T cell responses were measured by IFN-γ ELISpot assays in a large cohort of vaccine 
recipients. We observed a good correlation between the magnitudes of T cell responses detected by IFN-γ 
ELISpot and by CD8+ intracellular cytokine staining, which is not surprising since the vaccine 
preferentially induced CD8+ T cells, and the CD4+ T cells elicited primarily secreted IL-2 and TNF-α 
[2]. Although no SNP reached genome-wide significance, polymorphisms located in the MHC region 
showed the strongest association with responses to Gag, of all tested polymorphisms, leading us to look 
for possible associations between HLA class I alleles and that immunological outcome.  
 
Several HLA-B alleles were found to be responsible for the SNP-associated signal: HLA-B*2705, 
B*5101 and B*5701 associated with higher Gag responses, whereas HLA-B*0801 and B*4501 
associated with lower responses. Strikingly, all five alleles are also known to associate with differences in 
HIV-1 control [12]. HLA-B*57 is the human genetic factor that has been most consistently associated 
with potent control of HIV-1 [13-17], with B*5701 observed almost exclusively in Caucasians and 
B*5703 mostly found in individuals of African ancestry. There is clear epidemiological and functional 
evidence for effective restriction of HIV-1 by HLA-B*27 [18, 19]. HLA-B*5101 was also known to 
associate with slower progression to AIDS [20], and its protective effect was nicely confirmed in a recent 
study that showed that the allele drives HIV-1 adaptation at a population level [21]. Conversely, HLA-
B*0801 and HLA-B*4501 have both been associated with higher viral load and more rapid disease 
progression [20, 22, 23]. The identification of the same HLA alleles, acting in comparable directions, 
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strongly suggests that overlapping mechanisms are implicated in the development of vaccine-induced 
cellular immunity to HIV-1 and of natural immune control of HIV-1. Of course, the ELISpot results used 
in this study only provide information about the immunogenicity of the vaccine, and do not represent a 
correlate of protection for the tested vaccine. It is possible that the vaccine elicited appropriate CD8+ T 
cell immune responses to enhance viral control, as suggested by recent data [24], but that these are either 
too weak in function or magnitude, in too small a subset of the population, or both to confirm 
meaningfully enhanced control at a population level. 
 
Comparable results had been reported previously in an immunogenetic study of an HIV-1 vaccine. 
Responses to HIV-1 proteins were measured in samples from ALVAC-HIV recombinant canarypox 
vaccine trials using a lytic cytotoxic T-lymphocyte assay, and the proportions of samples responding to 
Gag or Env were found to be significantly higher among those carrying HLA-B*27 or B*57 [25]. The 
canarypox T cell vaccine that was used was poorly immunogenic for eliciting CD8+ T cells and the study 
population was smaller, still the concordance between our observations and those earlier results 
strengthens the case for an important role of protective HLA-B alleles in differential cellular immune 
responses to HIV-1 vaccines. 
 
 
Gag-specific CD8+ T-cell responses have repeatedly been related to improved immune control of HIV-1 
infection [12, 26, 27], explained largely because Gag is both highly immunogenic and highly conserved in 
sequence, and because mutational escapes often result in a decrease in viral fitness. The results presented 
here show that Gag-specific immune responses to T-cell vaccines are modulated by the host 
immunogenetic background. HLA class I typing data should thus be discussed at the design stage and 
included in the analysis of future studies of candidate vaccines eliciting robust CD8+ T cells.    
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Finally, it is noteworthy that most of the inter-individual variation in cellular responses to the MRKAd5 
HIV-1 gag/pol/nef vaccine remains unexplained. To help understand the rest of the variation, it seems 
appropriate to perform additional studies, for example applying resequencing technology to uncover rare 
causal genetic variants, since we here confirmed the existence of a connection between natural viral 
control and vaccine response. 
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Footnotes 
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Table 1. Characteristics of study participants 
 Eligible In association  analyses 
Male gender, N (%) 831 (100) 768 (100) 
Vaccine recipient, N (%) 831 (100) 768 (100) 
Age, mean (SD) 30.4 (7.7) 30.4 (7.7) 
Circumcision, N (%)* 458 (55.8) 429 (55.9) 
HIV infection during trial, N (%) 36 (4.3) 34 (4.4) 
Ethnicity, N 
(%) 
White 410 (49.3) 375 (48.8) 
Black 84 (10.1) 76 (9.9) 
Hispanic American 72 (8.7) 69 (9.0) 
Asian 13 (1.6) 13 (1.7) 
Native American 8 (1.0) 7 (0.9) 
Polynesian 1 (0.1) 1 (0.1) 
Multi-racial 242 (29.1) 226 (29.4) 
Country, N 
(%) 
United States 484 (58.2) 449 (58.5) 
Peru 217 (26.1) 202 (26.3) 
Brazil 50 (6.0) 47 (6.1) 
Canada 27 (3.3) 24 (3.1) 
Haiti 18 (2.2) 15 (2.0) 
Dominican Republic 13 (1.6) 11 (1.4) 
Australia 10 (1.2) 9 (1.2) 
Puerto Rico 10 (1.2) 10 (1.3) 
Jamaica 2 (0.2) 1 (0.1) 
* Information missing for 10 subjects
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Table 2. Participants included in linear regression analyses, by ethnic group. 
 
Ethnic 
group 
Total N 
Positive responses to 
any HIV-1 peptide pool 
Positive Gag-specific 
responses 
  N % N % 
Whites 318 283 89.0 265 83.3 
Blacks 87 72 87.8 59 73.0 
Mestizos * 115 101 82.8 84 67.8 
 
* Mestizo (“mixed race”) is used by Peruvians to describe their ethnic group.
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Table 3. The HLA-B alleles HLA-B*2705, *5101, *5701, *0801 and *4501 together explain most of 
the genome-wide association signals detected in the region. Results are shown for the 5 most 
associated SNPs in the analysis of Gag-specific responses in whites. All linear regression models include 
age, Ad5 titers, laboratory (HVTN vs. Merck) and EIGENSTRAT values as covariates. The adjusted P 
value (‡) is obtained for each SNP in a model in which the 5 HLA-B alleles are incorporated.  
 
Top 5 SNPs in 
GWAS  
P values for SNP associations 
GWAS P value Adjusted P value ‡ 
rs4713462  1.9E-06 0.02 
rs4713460  2.4E-06 0.03 
rs2247056  1.4E-05 0.07 
rs2853935  1.4E-05 0.06 
rs2523535  2.2E-05 0.11 
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Figure legends 
 
Figure 1. Comparison between Gag-specific ELISpot and ICS results: IFN-γ ELISpot and CD8+ T 
cell IFN-γ/IL-2 ICS results strongly correlate (upper panel), whereas there is no correlation between IFN-
γ ELISpot and CD4+ T cell IFN-γ/IL-2 ICS results (lower panel). 
 
Figure 2. Genomic overview of the MHC region that includes the most associated variants. Indicated 
are the P values [-log10(P)] for association with Gag-specific responses of all genotyped SNPs in the 
region and the structures of the surrounding genes. A P value <5E-08 was required to declare significance 
at the genome-wide level. 
 
Figure 3. HLA-B alleles associated with quantitative T cell responses to Gag in the IFN-γ ELISpot 
assay. Only white participants are included. 
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